Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05443594 · ClinicalTrials.gov registry record · NA
A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 669
- Enrollment target
NCT05443594 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 669 participants.
The verdict
NCT05443594, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 669 participants
- Enrollment target
Study Summary
The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).
Interventions
- DEVICE Phase 1: FARAPULSE Ablation System
- DEVICE Phase 2: FARAPULSE Ablation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 669 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-02-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05443594
The ClinicalTrials.gov registry entry for NCT05443594 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 669 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Phase 1: FARAPULSE Ablation System is the first listed.
NCT05443594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05443594 about?
NCT05443594 is a clinical study titled "A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation". The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).
What is the current status of trial NCT05443594?
This trial is currently completed. It is a NA study. The enrollment target is 669 participants. The study started on 2023-02-28. Estimated completion is 2025-02-11.
What interventions are being tested in trial NCT05443594?
The interventions under investigation include: Phase 1: FARAPULSE Ablation System (DEVICE), Phase 2: FARAPULSE Ablation System (DEVICE).
Who is sponsoring clinical trial NCT05443594?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.